Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B

Gut and Liver

Volumn 7, Issue 3, 2013, Pages 329-334

  Kim, Do Young ^a,b   Chang, Hye Young ^a   Lim, Sun Min ^a   Kim, Seung Up ^a,b   Park, Jun Yong ^a,b   Kim, Ja Kyung ^a,b   Lee, Kwan Sik ^a,b   Han, Kwang Hyub ^a,b   Chon, Chae Yoon ^a   Ahn, Sang Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

Author keywords

Adefovir; Entecavir; Hepatitis B virus; Lamivudine; Quasispecies

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; SEROCONVERSION; STRUCTURAL GENE; TREATMENT RESPONSE;

EID: 84879394570     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.3.329     Document Type: Article

References (23)

1. Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 2007;14 Suppl 1:11-15. (Pubitemid 47624107)
2. Cane PA, Mutimer D, Ratcliffe D, et al. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther 1999;4:7-14. (Pubitemid 29178919)
3. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68. (Pubitemid 28304879)
4. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263. (Pubitemid 29489740)
5. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
6. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000;31:219-224. (Pubitemid 30033710)
7. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755. (Pubitemid 36397384)
8. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
9. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. (Pubitemid 43357805)
10. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. (Pubitemid 43357804)
11. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838. (Pubitemid 35408307)
12. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-1665. (Pubitemid 44953670)
13. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006;26:162-170. (Pubitemid 43668258)
14. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-911. (Pubitemid 46355274)
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45: 507-539. (Pubitemid 46374607)
16. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006;78 Suppl 1:S52-S55. (Pubitemid 43993466)
17. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-586. (Pubitemid 32328516)
18. Jardi R, Rodriguez-Frias F, Schaper M, et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 2007;14:835-840. (Pubitemid 350211405)
19. Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat 2011;18:e212-e216.
20. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-712. (Pubitemid 44433727)
21. Moriconi F, Colombatto P, Coco B, et al. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother 2007;60:341-349. (Pubitemid 47243884)
22. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507. (Pubitemid 39129351)
23. Guo JJ, Li QL, Shi XF, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res 2009;81:180-183.